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Reveiw Article 
EpCAM,an old cancer antigen,turned oncogenic receptor and its tageting immunotherapy 
 
Abstract 
EpCAM is a cell adhesion molecule.Its structure,its expression and the oncogenic potential,and its 
signaling network and target therapy were in concise reviewed.In recent advances,in addition to 
PI3K/akt and Raf/MAPK pathway involving in cell survival,anti-apoptosis and proliferation,and 
malignant initiation and progression(see figure by Zhu,1986-91),three distict pathway are 
illustrated:EpCAM/E-cadherin-catenin-actin cytoskeleton,EpCAM/wint-catenin signaling,and its 
major EpCAM/nuclear signaling presented by Maetzel D in 2009 and Munz M in 2004. 
Moreover,more accumulated data are needed in detail mechanism.The data may provide its cancer 
biology and clinical targeting therapy benefits. 
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Introduction 
In a series of long list of oncogenic receptors which discriminated tumorigenic in partial origin of 
tumours from receptors in normal health people and then better to potential targeting therapy benefits 
are presented in clear in previous references[table 1,1-6]. Because It is no need to targeting receptors 
in normal condition,actually,targeting therapy[7]now is shift mainly toward oncogenic receptors in 
tumours in tumor hospitals,even if we won't citing in literature. 
Table 1.Receptors with oncogenic potential associated with tumours(also receptor-mediated tumorigenesis) 
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 EpCAM molecule,a novel oncogenic receptor[34]is shift toward new member family and targeting 
its antibodies.In this paper,I am delibrating recent advances on EpCAM in this field. 
 
Growth factors receptors: Oncogenic receptor EGFRvIII（GB,MLC,SCC）[8-11], Oncogenic receptor MUC1[12] or 
MUC4[12], Neu oncogenic receptor（breast cancer）[13];Oncogenic receptor IGF-1R; Oncogenic B receptor（HCD,CLL）
[14],and other VEGFR2(colorectal cancer,glioma) 
 
Cytokine receptors: Oncogenic growth hormone receptor（gigantism,acromegaly）[15]; GHRH/GHRHR oncogenic signaling
（pituitary tumors）;  Oncogenic EPOR（PFCP）[16],oncogenic EPOR-IGH/IGK fusion（BCP-ALL）[17]; Oncogenic CSF3R
（CNL or aCML）[18]; IL-2-BCM fusion（T cell lymphoma）;IL-3-IgH oncogenic fusion（ALL）; IL-11/IL-11 receptor（gp130 
Y757F/Y757F）pro-oncogenic signaling（gastric tumor in mice)[19,20]; IL-21R-BCL6 fusion（DLBCL,lymphoma cell 
line）;Oncogenic TSHR（thyroid adenoma） 
 
Steroid receptors: Oncogenic thyroid hormone receptor（TR）（PTC）[21],oncogenic THR1/BTR fusion（breast cancer cell 
line）;oncogenic receptor pml/RARa （APL）[22,23];Oncogenic receptor AR variants（Pca）[24,25]; ER pro-neoplastic 
signaling[26,27],neoplastic ESR1-CCDC170 fusion(also oncogenic receptor ERalpha fusion)（breast cancer）[7,28];GRβ 
aberrant signaling（Cushing's disease,erythrocytosis,GR+ breast cancer,Nelson's syndrome）[29-31];FSH/FSH receptor 
oncogenic signaling（preneoplastic ovarian surface epithelial cells) 
 
 
Others: Pro-oncogenic receptor CLC1[32]; 
 
 
Tobacco related cancer（toxicology）: nicotinic acetylcholine receptor alpha7-nAchR oncogenic receptor[33] 
 
  
 
EpCAM structure 
 
The epithelial cell adhesion molecule[EpCAM,35]was originally identified as a tumor associated 
antigen in discovery in 1970s[36],also known as cluster of differentiation 326（CD326）,and 
tumor-associated calcium signal transducer 1（TACSTD1）[37].EpCAM is a type I transmembrane 
protein of 314 amino acids（aa）with apparent molecular weight of 40kd.The extracellular domain
（ EpEX ） contain epidermal growth factor-like domain, a thyroglobin （ TY ） repeat 
domain,tansmembrane domain（TM）,and a short 26-amino acid intracellular domain（EpICD）（see 
figure 1）[34,37].  
 
EpCAM is an oncogenic receptor[34]that requires regulated intramembrane proteolysis for activation 
of its signal transduction capacity. EpCAM cleavage is dependent on cell-to-cell 
contact.Thus,EpCAM as an oncogenic signaling protein[37]engaged in cell adhesion and nuclear 
signaling[38]. 
 
EpCAM expression,a dual player 
EpCAM is expressed by the epithelium of health individuals（all simple, pseudo- stratified and 
transitional epithelia）,except by squamous epithelium,and some specific epithelial cell types,such as 
hepatocytes and keratinocytes[39].EpCAM is a membrane protein with proto-oncogenic properties 
that is expressed in most human carcinomas,EpCAM is overexpressed to varying degrees[40].These 
include the majority of adenocarcinomaas including pancreatic adenocarcinoma, cholangiocarcinoma, 
node-positive breast cancer, epithelial ovarian cancer,lung cancer,colon carcinoma,prostate 
cancer,gastric cancer,hepatic carcinoma and squamous cell head and neck 
cancer[41-43].Recently,EpCAM has been identified as an additional marker for cancer-initiating 
stem cells[44-46]. 
The oncogenic potential of EpCAM or EpICD was demonstrated in a mouse xenograft model,in 
  
which HEK 293 cells stably expressing EpCAM or EpICD produced nearly equivalent large 
tumours,whereas control cells only formed a small tumour in a single case[38].EpCAM expressing 
pancreatic cancer stem cells showed a 100-fold enhanced tumorigenic potential compared with 
EpCAM-negative pancreatic cancer stem cells[47,48].Similarily,in vivo evaluation of tumorigenicity 
in hepatocellular carcinoma cell lines,using immunodeficient NOG mice,a smaller number of 
EpCAM+ cells（minimum 100）than EpCAM- cells are able to tumor formation.The introduction of 
exogenous EpCAM into EpCAM+ clones,but not into EpCAM- clones,markedly enhanced their 
tumor-forming ability[45].Also, EpCAM-positive hepatocellular carcinoma stem cells could 
efficiently initiate tumours in SCID mice[46].Very recent, EpCAM-proliferating ductal cells（PDC）
give rise to hepatocellular carcinoma（HCC） in the inflamed liver[48],which provide direct 
experimental evidence that EpCAM expressing PDC could be a cellular origin of HCC,suggesting 
the existence of stem/progenitor-derived hepatocarcinogenesis. For breast cancer stem cells,the 
ability to form tumours in SCID mice was for EpCAM+ cells 50-fold greater compared with the 
unfractioned tumour cells[47].Therefore,although EpCAM- and EpCAM+ cancer stem cells were 
able to form tumours,10-fold less EpCAM+ cells than EpCAM- cells were able to induce 
tumours.Indeed,EpCAM overexpression is associated with decreased overall survival of patients 
with a broad variety of carcinoma[42,47]. 
In contrast to its promoting role regarding tumour formation,high EpCAM expression only in two 
tumour types（renal clear cell carcinoma and thyroid carcinoma）has been consistently associated 
with improved patient survival[47,49]. 
Signal transduction by EpCAM oncogenic receptor and its target pathway 
Several biological function of EpCAM have been described.EpCAM is a cell adhesion molecule,its 
action was invented in fact,is not limited on adhesion between cell and cell,and also can activate 
intracellular MAPK and PI3K/Akt signal,to cause tumor cell proliferation,invasion and metastasis 
etc. biological action（see figure 2,George Zhu,1991; Hu etal,2012）.Recent advances further  
uncovers a highlight of new data in its distinct signal pathway. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
EpCAM/E-cadherin-catenin-actin cytoskeleton（E-cadherin-mediated adhesion） 
 
Adhesion molecules are known to play an important role in definiting cell fate,differentiation and 
other biological characteristics[50].EpCAM is a Ca2+--independent homotypic intercellular adhesion 
molecule[35],thereby preventing cell scattering and likely to play a role in inhibition of 
invasion[51].Many studies have demonstrated that cadherin colocalized with EpCAM at the 
basolateral membrane in epithelial cells decrease adhesions mediated by E-cadherin,a family of 
Ca2+--dependent homophilic cell-to-cell adhesion molecule.In epithelia,cadherins are crucial for the 
establishment and maintenance of epithelial cell polarity,morphogenesis of epithelial tissues,and 
regulation of cell proliferation and apoptosis[50] 
Furthermore,the adhesion function of E-cadherin depends on their association with regulatory 
proteins,such as alpha- and beta-catenin[50,52].Catenins link cadherins with the actin cytoskeleton 
and can also form complexes with other epidermal growth factor receptor （ EGFR ）
protein[52,53].EpCAM is able to abrogate E-cadherin- mediated cell-cell adhesion by disrupting the 
link between alpha-catenin and F-actin thereby loosening cell-cell adhesion and to rearrange the 
cytoskeleton of the cell[39].This negative effect of EpCAM expression on cadherin-mediated 
adhesion may explain the association of EpCAM expression with invasion and metastasis in 
epithelial carcinoma[41].EpCAM SiRNA treatment increased the cytoskeleton-anchored fractions of 
E-cadherin,alpha-catenin and beta-catenin,then markedly decreased cell migration and cell invasion 
in the breast cancer cell line MDA-MB-231 in vitro[41],which implicated that EpCAM as a regulator 
of cell adhesion is a potential novel target for breast cancer therapy. 
Figure 2. A Scheme of oncogenic receptor (or receptor) mediated 
multiple signal transduction. Here, nuclear regulators include 
transcriptional factors such as Jun/AP-1:Fos,NF-KB,myc,p53 and RB so 
on [Data from George Zhu,1986-91; Science,2002(unpublished data)] 
  
 
 
EpCAM/wnt-beta-catenin signaling[41,54] 
 
Wnt proteins are a family of highly conserved signaling molecules that regulate cell-to-cell 
interaction during embryogenesis. Wnt binds to receptors of the Frizzled family on the surface. 
Through several cytoplasmic relay components,the signal is transduced to beta-catenin,which 
accumulate initially in the cytoplasm,and then enters the nucleus,where it binds a lymphoid enhancer 
factor/T-cell factor transcriptional factor. The beta-catenin and lymphoid enhancer factor/T-cell 
factor complexes activate the expression of many target genes such as c-myc,VEGF and others,are 
known to be associated with tumor development[54].It has been demonstrated that EpCAM silencing 
in breast cancer cells decreased the availability of beta-catenin for the wnt pathway and then 
silencing the activation of its target genes[41].This notion is also supported by Yamashita[46] in 
patients with hepatocellular carcinoma and Kimura[45]in hepatocellular carcinoma cell lines.Their 
experiments uncovered that EpCAM-associated tumorigenicity in PLC/PRF/5 cells might be 
mediated by EpCAM-independent signaling due to the immunostaining failed to detect EpICD and 
EpCAM molecules in the nuclei of any cell clones from the PLC/PRF/5 cell lines[45].Moreover,the 
hepatic stem cell marker EpCAM knockdown in EpCAM+ cells reduces their colony-forming 
ability,suggesting an important role for EpCAM in the EpCAM+ cells,and,regardless of the 
exogenous expreasion of EpCAM,EpCAM+ clones still had higher expression of c-myc,than the 
EpCAM-overexpressing EpCAM- clones. Therefore,signals through EpCAM induce 
Wnt/beta-catenin activation might be involved to another different signaling pathway in 
tumorigenesis under certain condition[45,46] 
 
 
EpCAM nuclear signaling 
 
A highlight of new data presented by M. Munz that unravelled the entire pathway of EpCAM 
signalling from the cell membrane into nucleus[55].EpCAM was identified as a signal transducer[38]: 
regulated transmembrane proteolysis by tumor necrosis factor-alpha-converting enzyme（TACE）
cleaves EpEX,and EpICD is cleaved by presenilin-2. Upon cleavage,the extracellular domain EpEX 
is release as a soluble ligand while the intracellular domain EpICD translocates into the cytoplasm 
and enter the nucleus. EpICD associates with the adaptor protein FHL2（four and a half LIM domain 
protein 2）,beta-catenin and the transcription factor Lef-1. This transcription complex binds the DNA 
at the lef-1 consensus sites inducing target genes c-myc and cyclin A and E expression[38],and 
drives cell proliferation. This notion is supported by the EpCAM found in nuclei of colon carcinoma 
but not of normal tissue[38],and HCT（colon）and MCF-7（breast）carcinoma cells[34].In 
addition,analysis for concomitant presence of claudin 7,Co-029,CD44V6 and EpCAM expression in 
the presence of all four molecules in a complex formation was initially found in colorectal cancer
（CRR）and has been shown to facilitate metastasis[56]. 
  
  
Others,epithelial-specific Ets-1 and Sp1 play an active role in EpCAM promoter regulation 
[37],while transcription factor nuclear factor-kappa B（NF-KB）and p53 have been described as 
transcriptional repressor of EpCAM[47].TACE-dependent EGFR axis[57],Claudin-7 and claudin-1 
trafficked into lysosomes[58]and presenillins mediate PI3K/akt and ERK activation via select 
signaling receptors[59],which present a highlight mechanism in cancer. 
 
The emerging function of EpCAM in cell proliferation,migration and possibly cancer initiation 
broadens the interest to use EpCAM as an immunotarget,antibody-based clinical trials and in 
2009,the European Medicines Agency approved the use of trifunctional bispecific antibody 
Catumaxomab,which binds to EpCAM oncogenic receptor and enhances the immunological 
response against EpCAM-positive cells in malignant ascites[43]. Effects of monoclonal antibody 
immunotherapy was initially trials on patients with gastrointestinal adenocarcinoma[60],three of 20 
patients with metastasis of gastrointestinal malignancies have no detectable disease for 10,13 and 22 
months due to the treatment with an anti-colorectal cancer mouse monoclonal antibody 1083-17-1A 
of the IgG2a immunotherapy.  
 
In 1989-91,Zhu[1]is the first to conduct that targeting therapy is shift toward oncogenic eeceptor[also 
surface-to-nucleus molecular missile therapy at that period,Zhu,1980s;34,61]   
In 1994,mAb17-1A（later named edrecolomab）was also the first to show clinical efficacy in a human 
cancer indication in terms of prolonged overall survival[62]. 
Now, several anti-EpCAM therapeutic antibodies have been developed（edrecolomab,ING-1, 
3622W94, adecatumumab）[63].The most prominent examole is adecatumumab（MT201）,a fully 
human IgG1 antibody that target oncogenic EpCAM,which was well tolerated by patients with 
hormone-refractory prostate cancer[43]and in patients with rising prostate specific antigen（PSA）
levels after radical prostatectomy[43].It is at present reaching phase III trial[64].  
In preclinical study,moreover,high doses of chiHEA125-Ama （ 100ug/kg with respect to 
alpha-amanitin）administered 1 week apart,lead to complete tumor regression in 9 of 10（90%）
mice,suggesting that anti-EpCAM antibody conjugates with alpha-amanitin have the potential to be 
highly effective therapeutic agents for pancreatic carcinoma and various EpCAM-expressing 
malignancies[43].Targeting EpCAM oncogenic receptor might be a promising approach to stop 
tumor initiation,invasion and progression. 
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